Dear Daniel and all,

Did anyone happen to review and perhaps have some ideas about the following article on OncologyCentral, reporting an article from nature?

OncologyCentral report:

https://www.oncology-central.com/subject-area/preclinical-research-and-trials/old-drugs-new-tricks-several-non-oncology-drugs-can-kill-cancer-cells/

nature full article about the study:

"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling"

https://www.nature.com/articles/s43018-019-0018-6

Briefly,

"In this study, researchers examined the entire collection of clinically approved, mostly non-cancer drugs at the Broad’s Drug Repurposing Hub, in order to establish whether any had anti-cancer properties."

The researchers analyzed ~4500 compounds from the Drug Repositioning Hub on 578 human cancer cell lines. They used PRISM (profiling relative inhibition simultaneously in mixtures) method, to screen drugs against cell lines in pools.

I'm only in the middle of reading this article but I already find this as very interesting on its own with some specific information, such as: Predictive biomarkers of disulfiram activity (which I was not aware of so far), which might influence the considerations for using disulfiram.

Also, so far I arrived from this article to other two resources (that you might already know?) and seems interesting at 1st look (and hopefully helpful):

From the BROAD institute of MIT & Harvard -

• Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling:  https://depmap.org/repurposing
• The Drug repurposing Hub:  https://clue.io/repurposing    https://clue.io/repurposing-app

I would appreciate sharing your ideas and insights if you choose to review this article and these information resources.

Many thanks and best wishes!

Nissim